Novo Nordisk Aims for the Top: CagriSema Poised for Breakthrough US$ 22.88 Min. order: 1 piece ★★★★★ 5.0 (236 reviews) Sold : Login>>
Novo Nordisk Offers New Contender in Weight Management US$ 26.12 Min. order: 1 piece ★★★★★ 4.2 (172 reviews) Sold : Login>>
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.8 (47 reviews) Sold : Login>>
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' – NBC Connecticut US$ 20.10 Min. order: 1 piece ★★★★★ 4.8 (35 reviews) Sold : Login>>
Based on the early promising data for injectable cagrilintide-semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP-1 Amylin Amycretin peptide in healthy PPL with overweight and #obesity in P1 US$ 25.36 Min. order: 1 piece ★★★★★ 4.4 (300 reviews) Sold : Login>>